Enhancement	O
of	O
skin	B-Organ
permeation	O
of	O
ketotifen	O
by	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
of	O
the	O
drug	O
.	O

Pressure	O
sensitive	O
adhesive	O
(	O
PSA	O
)	O
matrices	O
containing	O
amorphous	O
ketotifen	O
were	O
prepared	O
and	O
evaluated	O
for	O
enhanced	O
skin	B-Organ
permeability	O
of	O
the	O
drug	O
.	O

A	O
solvent	O
casting	O
method	O
using	O
silicone	O
-	O
typed	O
PSA	O
was	O
employed	O
,	O
and	O
n	O
-	O
hexane	O
,	O
an	O
original	O
solvent	O
for	O
the	O
PSA	O
and	O
one	O
more	O
solvent	O
,	O
dichloromethane	O
,	O
tetrahydrofuran	O
,	O
acetone	O
,	O
ethyl	O
acetate	O
or	O
toluene	O
,	O
were	O
used	O
for	O
complete	O
dissolution	O
of	O
ketotifen	O
and	O
high	O
dispersion	O
in	O
an	O
amorphous	O
state	O
of	O
the	O
drug	O
.	O

Presence	O
of	O
the	O
amorphous	O
form	O
was	O
judged	O
based	O
on	O
the	O
in	O
vitro	O
drug	O
release	O
rate	O
from	O
the	O
matrix	O
.	O

As	O
a	O
result	O
,	O
dichloromethane	O
and	O
tetrahudrofuran	O
were	O
selected	O
as	O
appropriate	O
dilution	O
solvents	O
.	O

In	O
vitro	O
permeation	O
experiments	O
through	O
excised	O
hairless	O
mouse	O
skin	B-Organ
revealed	O
that	O
the	O
steady	O
-	O
state	O
flux	O
from	O
the	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
was	O
about	O
five	O
times	O
greater	O
than	O
that	O
of	O
the	O
crystalline	O
ketotifen	O
-	O
dispersed	O
matrices	O
,	O
and	O
that	O
the	O
enhancement	O
ratio	O
was	O
in	O
good	O
agreement	O
with	O
the	O
solubility	O
ratio	O
of	O
the	O
amorphous	O
to	O
crystalline	O
form	O
of	O
the	O
drug	O
.	O

Comparison	O
of	O
the	O
skin	B-Organ
permeation	O
profiles	O
of	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
between	O
two	O
different	O
drug	O
contents	O
suggested	O
that	O
the	O
steady	O
-	O
state	O
flux	O
was	O
not	O
influenced	O
by	O
the	O
drug	O
content	O
.	O

In	O
addition	O
,	O
at	O
both	O
drug	O
contents	O
,	O
the	O
period	O
of	O
the	O
steady	O
-	O
state	O
permeation	O
coincided	O
with	O
the	O
time	O
until	O
the	O
amorphous	O
drug	O
was	O
depleted	O
from	O
the	O
matrix	O
.	O

These	O
results	O
suggest	O
that	O
the	O
increase	O
in	O
skin	B-Organ
permeation	O
of	O
ketotifen	O
from	O
PSA	O
matrix	O
was	O
due	O
to	O
the	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
,	O
and	O
that	O
the	O
amorphous	O
form	O
was	O
stable	O
during	O
the	O
application	O
period	O
.	O

